UBS cuts AnaptysBio stock price target to $60 on business spinoff

ANAB is transitioning from a development-stage biotech to a royalty monetization vehicle, which should materially compress the range of outcomes: lower operating risk, but also a lower ceiling unless the royalty asset can compound faster than the market expects. The key second-order effect is that the stock may start trading less like biotech and more like a small-cap yield/security with a duration-like cash flow stream; that tends to attract a different shareholder base and can support multiple expansion if the company actually behaves like capital-return machinery.

The main driver is now concentration risk. A single royalty stream tied to Jemperli becomes the entire equity story, so any incremental adoption inflection or label expansion can move the stock disproportionately, while any commercial disappointment will be punished harder because there is no pipeline diversification left to cushion it. That makes the next 2-4 quarters about estimating whether royalty growth can offset the inevitable decline in the “spinco” novelty premium and whether management can credibly translate net cash into accretive capital returns.

For GSK, the spillover is modest but directionally positive: if Jemperli keeps scaling, the royalty obligation is a manageable economic drag relative to the value created by greater product traction. The sharper implication is for other royalty-heavy biotech assets: investors may re-rate them if ANAB begins to trade on cash flow yield rather than headline biotech multiples. Conversely, if ANAB fails to hold above a low-teens EV/royalty framework, it would signal the market still demands pipeline optionality even for so-called pure plays.

The contrarian point is that the move may be partially over-earned already: the stock has already priced in a lot of the “clean-up story,” so the next leg likely requires visible royalty acceleration, not just simplification. Without a near-term capital-return catalyst, the shares can drift as event-driven holders rotate out after the corporate action settles.